AMAG Pharmaceuticals Announces the Publication of the Phase 3 Vyleesi™ (Bremelanotide Injection) Data in Obstetrics & Gynecology

by NASDAQ Market News October 11, 2019

NASDAQ Market News
Click here to email author

RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease

Biased Views of Obesity Leave Canadians Unsupported at Work and in the Doctor’s Office: Study

Ads